Therapeutic methods for the treatment of prostate cancer are described. The methods include a gene therapy method for prostate cancer using the BRCA family of genes, including the BRCA1 and BRCA2 genes. The BRCA family of gene products inhibit the growth and tumorigenesis of prostate cancer cells. Therapeutic methods using the BRCA family of gene products are also described.
In accordance with the present invention, there are provided amphiphilic polyamine compounds and derivatives thereof having the property of promoting transfection of polynucleotides and polypeptides into cells, and formulations comprising said compounds.
A novel method of treating human diseases using natural products found in roasted coffee. The use of natural products or derivatives thereof would permit the general public to improve their health without having to use prescription drugs.
The mutant SERTs we have developed can provide for a platform to screen for novel modes/molecules interrupting SERT function. As SERT blockers are effective antidepressants, this strategy can lead to novel antidepressant medications. It may also be useful in development of animal models to test antidepressant action in vivo.
The mutation allows for the first genetic test to be conducted for one form of chronic fatigue or mitral valve prolapse which we describe as orthostatic intolerance or postural tachycardia syndrome (POTS). The technology allows for the development of this test and the development of other tests in the same gene at other loci that may contribute to similar illnesses. The awareness of a phenotype associated with the mutation in the antidepressant-sensitive NET allows for evaluation of the role of the NET gene in mental illness and thus the development of genetic tests for increased susceptibility to mental and autonomic illnesses. This is the first neurotransmitter transporter gene defect that has been shown to be linked to a disorder. The precedent act opens the door for screening for other genetic mutations in genetically related transporters such as the serotonin transporter or dopamine transporter. These latter transporters have been implicated in depression anxiety, pscyhostimulant abuse (cocaine/amphetamine) and attention-deficit disorder. Our work allows for genetic inspection of transporter genes associated with these disorders. Our work may also allow for an examination of whether circulating antibodies against the NE transporter are contributory to OI or other chronic fatigue disorders.
In 2009 over 70,000 American were diagnosed with urinary bladder cancer, and in that same year over 14,000 Americans died of bladder cancer. Low funding for bladder cancer helps explain the slow progress in both the identification of biomarkers and the development of new treatments for metastatic bladder cancer. Nonetheless, novel diagnostic biomarkers are needed to aid in the early identification of patients with bladder cancer, and also to determine which patients are likely to progress. Vanderbilt researchers have identified such a biomarker whose expression is reduced and lost during progression of bladder cancer.
Vanderbilt researchers, led by Eric Skaar, Ph.D., have identified novel compounds that are antimicrobial. These compounds represent a first in class as they target a new bacterial pathway that has never been targeted as an antimicrobial strategy.
Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g., anxiety, epilepsy, schizophrenia and other psychotic disorders, Parkinson's disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5 antagonist compound of the invention.
Since the discovery of antibiotics in the 1940' and 1950's no signifi cant advances have been made in the treatment of wounds. One of the most formidable challenges to effecting tissue repair and regeneration is to direct the orchestrated proliferation and organization of multiple cell types to recapitulate structure and function of the damaged organ. Pampee Young, Ethan Lee and colleagues have data to show that modulations of tissue resident stem cells represent a central mechanism that impacts repair and regeneration.
The technology described here permits the delivery of therapeutic or diagnostic (tumor imaging) molecules to a variety of tumor types in a targeted fashion. Current methods for targeting therapeutic agents to tumors have limited utility because they (i) produce toxic effects through reactions with normal tissues; (ii) lack the ability to bind to multiple tumor types and/or (iii) lack tumor specificity. This technology is based upon the fact that certain proteins are upregulated in blood vessels in response to irradiation. These upregulated proteins can act as targets for binding molecules such as antibodies, peptides, or other chemicals. Attaching an anti-tumor therapeutic unit, such as a radioisotope, to one of these binding molecules (e.g. an antibody) provides a way to treat or detect a variety of tumor types and stages while avoiding damage to normal tissue. Licensing Opportunity: A suite of patents and patent applications available for licensing includes compositions of radiation-inducible tumor proteins, and molecules that bind these proteins such as peptides and antibodies; along with methods of using these ligands for treatment and for identification of radiation inducible ligands in tumors. State of development/future plans: Screening a phage display library (murine) has resulted in production of 13 recombinant antibodies that bind to an identified radiation-inducible antigen. Only 2 (designated Lead and Control ScFv) of the 13 recombinant antibodies bound radiation-induced antigen in mice and are depicted in the accompanying figure. Of these two, the LEAD ScFv specifically bound tumor (see figure). Research is moving towards humanizing the lead antibody and identifying the specific epitope bound by the antibody.
The present invention provides a method of making particles useful in drug delivery, comprising the steps of: contacting polyanionic polymers with cations in a stirred reactor so that polyanions and the cations react to form particles.
Methods and apparatuses for analyzing proteins and other biological materials and xenobiotics within a sample. A specimen is generated, which may include an energy absorbent matrix. The specimen is struck with laser beams such that the specimen releases proteins. The atomic mass of the released proteins over a range of atomic masses is measured. An atomic mass window of interest within the range of atomic masses is analyzed to determine the spatial arrangement of specific proteins within the sample, and those specific proteins are identified as a function of the spatial arrangement. By analyzing the proteins, one may monitor and classify disease within a sample.Australia Patent 2002362961